My Watchlist

Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.

Recs

0

EU Deja Vu for This Biotech’s Orphan Drug

By | More Articles
March 22, 2013 | Comments (0)

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

The steady stream of positive news coming from the EU's CHMP today did not extend to Isis Pharmaceuticals (NASDAQ: ISIS  ) and Sanofi (NYSE: SNY  ) . Unfortunately, the duo's drug Kynamro, which is FDA-approved for the treatment of Homozygous Familial Hypercholesterolaemia in the United States, failed to win the green light from the CHMP for the second time.

What does this mean for Isis and Sanofi? And does this make Isis more vulnerable to its competitor Aegerion Pharmaceuticals (NASDAQ: AEGR  ) ? Health-care analyst Max Macaluso dives into these issues in the following video.

What macro trend was Warren Buffett referring to when he said, "This is the tapeworm that's eating at American competitiveness?" Find out in our free report, What's Really Eating at America's Competitiveness. You’ll also discover an idea to profit as companies work to eradicate this efficiency-sucking tapeworm. Just click here for free, immediate access.

Jeff Fischer and team have demystified options. And they can rack up income like $1,030... $2,626... and $3,228 on a schedule you can set your watch by!
That's why we're glad to announce every single one of their closely guarded strategies is available to YOU during May and June – 100% FREE, no strings attached! Just enter your email address in the box below...

Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool recommends GlaxoSmithKline. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

DocumentId: 2328141, ~/Articles/ArticleHandler.aspx, 5/20/2013 11:48:49 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 15,377.69 23.29 0.15%
S&P 500 1,671.31 3.84 0.23%
NASD 3,507.46 8.49 0.24%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

5/20/2013 11:32 AM
SNY $54.29 Down -0.21 -0.39%
Sanofi (ADR) CAPS Rating: ****
ISIS $20.75 Up +0.09 +0.44%
ISIS Pharmaceutica… CAPS Rating: **
AEGR $60.96 Down -0.61 -0.99%
Aegerion Pharmaceu… CAPS Rating: **

Advertisement